Sugi Predict

Sugi Predict / Compounds / SCHEMBL20003753

SCHEMBL20003753

SCHEMBL20003753

CCCCCCCCCCCCCCCC(=O)NCCOCCOCCOCCC(=O)NCCCCC1NC(=O)C(Cc2ccccc2)NC(=O)C(CCCCN)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C2CCCN2C(=O)C(Cc2ccccc2)NC(=O)C(Cc2c[nH]cn2)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)CC(C)C)C(C)O)CSSCC(C(=O)NC(CCCCN)C(N)=O)NC(=O)C(C(C)C)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C2CCCN2C1=O

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ PRLHR P49683 11/20 0.58
▸ EPHA2 P29317 1/20 0.56
▸ NPY2R P49146 2/20 0.54
▸ RXFP4 Q8TDU9 2/20 0.53
▸ RXFP3 Q9NSD7 2/20 0.53
▸ GLP1R P43220 4/20 0.53
▸ GCGR P47871 1/20 0.53
▸ CCKBR P32239 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27014090 0.91 TEAD1 (0.53) PRLHREPHA2NPY2RRXFP4RXFP3
SCHEMBL23056722 0.91 TEAD1 (0.53) PRLHREPHA2NPY2RRXFP4RXFP3
SCHEMBL20402542 0.91 MC4R (0.53) EPHA2NPY2RRXFP4RXFP3GLP1R
SCHEMBL20003972 0.91 MC4R (0.53) EPHA2NPY2RRXFP4RXFP3GLP1R
SCHEMBL20003971 0.89 GLP1R (0.51) NPY2RGLP1RGCGRCCKBR
SCHEMBL20003981 0.88 MC4R (0.50) EPHA2NPY2RRXFP4RXFP3GLP1R
SCHEMBL23056750 0.86 GLP1R (0.51) NPY2RGLP1RGCGRCCKBR
SCHEMBL26952437 0.85 MC4R (0.59) NPY2RGLP1RGCGR
SCHEMBL29461365 0.78 KLK5 (0.57) PRLHRNPY2RRXFP4RXFP3GLP1R
SCHEMBL14550392 0.76 TSLP (0.54) GLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016895-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE PROTAGONIST THERAPEUTICS, INC. 2024-01-18 — — US disclosed
US-10030061-B2 Hepcidin analogues and uses thereof PROTAGONIST THERAPEUTICS, INC. (US) 2018-07-24 — — US disclosed
US-20180086811-A1 HEPCIDIN ANALOGUES AND USES THEREOF PROTAGONIST THERAPEUTICS, INC. 2018-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10030061-B2 Hepcidin analogues and uses thereof HAMP, SLC40A1, FTH1 PRLHR 512/4885EPHA2 3953/4885NPY2R 985/4885
US-20240016895-A1 HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE HAMP, HBG1, HBG2 PRLHR 1954/4885EPHA2 3302/4885NPY2R 1042/4885
US-20180086811-A1 HEPCIDIN ANALOGUES AND USES THEREOF HAMP, SLC40A1, FTH1 PRLHR 513/4885EPHA2 3910/4885NPY2R 997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.